Pharma Archives - Page 65 of 76 - Life Sciences Times

PureTech Launches Celea Therapeutics to Advance Treatment of Serious Respiratory Diseases

August 12, 2025

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

August 11, 2025

Boston IVF Adds Dr. Mary Morris to Massachusetts Fertility Team, Expanding Expertise in Oncofertility and Family Building

August 7, 2025

THIS WEEK'S STORIES

Survey Finds Pediatricians Prefer Genexa’s Ingredient Profiles Over Children’s Tylenol® Products

August 13, 2025

ZAP Surgical Marks 5,000th Patient Treated with ZAP-X Gyroscopic Radiosurgery Platform

August 12, 2025

Merck’s KEYTRUDA-Padcev Combo Improves Survival for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients in Phase 3 Trial

August 12, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Pharma

Survey Finds Pediatricians Prefer Genexa’s Ingredient Profiles Over Children’s Tylenol® Products

Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award

Merck’s KEYTRUDA-Padcev Combo Improves Survival for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients in Phase 3 Trial

Akamis Bio Appoints C4 Therapeutics CEO Andrew Hirsch to Board of Directors

Study Points to New Mechanism for Schizophrenia Drug Candidate Evenamide

Most Read

KnoWEwell Names Functional Medicine Leader Dr. Patrick Hanaway as Chief Medical Officer

Survey Finds Pediatricians Prefer Genexa’s Ingredient Profiles Over Children’s Tylenol® Products

FDA Grants De Novo Authorization to ArteraAI Prostate, First AI-Powered Digital Pathology Tool for Prostate Cancer Prognosis

Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors

EDITOR PICKS

PureTech Launches Celea Therapeutics to Advance Treatment of Serious Respiratory Diseases

First Patient Dosed in Phase 3 Trial of Potential Dravet Syndrome Treatment

Boston IVF Adds Dr. Mary Morris to Massachusetts Fertility Team, Expanding Expertise in Oncofertility and Family Building

THIS WEEK'S STORIES

Survey Finds Pediatricians Prefer Genexa’s Ingredient Profiles Over Children’s Tylenol® Products

ZAP Surgical Marks 5,000th Patient Treated with ZAP-X Gyroscopic Radiosurgery Platform

Merck’s KEYTRUDA-Padcev Combo Improves Survival for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients in Phase 3 Trial

POPULAR CATEGORY

ABOUT US

FOLLOW US